<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637897</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000583652</org_study_id>
    <secondary_id>P30CA012197</secondary_id>
    <secondary_id>CCCWFU-74307</secondary_id>
    <nct_id>NCT00637897</nct_id>
    <nct_alias>NCT01055288</nct_alias>
  </id_info>
  <brief_title>Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>Feasibility of Dose Titrating Paricalcitol (Zemplar) in Women Receiving Taxanes or Ixabepilone for Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation, docetaxel,, paclitaxel, and ixabepilone work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Paricalcitol may help chemotherapy drugs to kill more tumor cells by making tumor cells more&#xD;
      sensitive to the drugs.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the best dose and best way to give paricalcitol and&#xD;
      to see how well it works when given together with chemotherapy in treating patients with&#xD;
      metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the ability to administer 8 continuous weeks of therapy within the first 3&#xD;
           months of enrollment with paricalcitol when given together with taxane or ixabepilone&#xD;
           therapy in women with metastatic breast cancer.&#xD;
&#xD;
        -  To estimate the proportion of patients who successfully complete 8 continuous weeks of&#xD;
           therapy as well as the proportion of patients who achieve a 'steady-state' dose.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine a dose of paricalcitol that can be taken continuously that maintains a&#xD;
           normal calcium level when combined with a taxane or ixabepilone.&#xD;
&#xD;
        -  To determine if baseline levels of 25-hydroxycholecalciferol and parathyroid hormone&#xD;
           (PTH) are associated with time to treatment failure in these patients.&#xD;
&#xD;
        -  To determine if PTH levels decline from baseline in patients treated with paricalcitol&#xD;
           in combination with taxane or ixabepilone therapy.&#xD;
&#xD;
      OUTLINE: Beginning on day 1, patients receive oral paricalcitol. The dose of paricalcitol is&#xD;
      increased every 2 weeks until the serum calcium level is between 9 mg/dL and 11.4 mg/dL. Once&#xD;
      this level is reached, the patient continues at that dose for the duration of the study.&#xD;
      Patients also receive paclitaxel albumin-stabilized nanoparticle formulation, docetaxel, or&#xD;
      paclitaxel once a week or once every 3 weeks or ixabepilone once every 3 weeks. Treatment&#xD;
      continues for at least 12 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical feasibility of therapy administration</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>To test the clinical/logistical feasibility of using a titrated dose of the vitamin D analog (paracalcitol or Zemplar) in combination with a taxane or ixabepilone primarily by measuring the proportion of patients who successfully complete 8 continuous weeks of therapy as well as the proportion of patients who achieve a 'steady-state' dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose of paricalcitol that maintains a normal calcium level when given in combination with a taxane or ixabepilone</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of baseline levels of 25-hydroxycholecalciferol and parathyroid hormone with time to treatment failure</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>To determine if baseline levels of 25(OH)D and parathyroid hormone are associated with time to treatment failure in patients treated with the combination of paricalcitol and a taxane or ixabepilone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of effect of combination of paricalcitol and a taxane or ixabepilone on parathyroid hormone levels failure</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>To determine if parathyroid hormone levels decline from baseline with the combination of paricalcitol and a taxane or ixabepilone</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paricalcitol (Zemplar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol (Zemplar)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Paricalcitol (Zemplar)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <arm_group_label>Paricalcitol (Zemplar)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Paricalcitol (Zemplar)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
    <arm_group_label>Paricalcitol (Zemplar)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
    <arm_group_label>Paricalcitol (Zemplar)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Metastatic or recurrent disease&#xD;
&#xD;
               -  Patients with bone metastasis only are eligible and evaluable for time to&#xD;
                  progression&#xD;
&#xD;
          -  Candidate for taxane or ixabepilone therapy&#xD;
&#xD;
          -  At least one lesion that can be measured in at least one diameter ≥ 2 cm by CT scan&#xD;
&#xD;
          -  No symptomatic brain metastases or other symptomatic CNS metastases&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 2.0 g/dL&#xD;
&#xD;
          -  Albumin corrected serum calcium &lt; 10.5 mg/dL&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 1 year after&#xD;
             study participation&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy or radiation therapy&#xD;
&#xD;
          -  Prior and concurrent taxane or ixabepilone therapy allowed&#xD;
&#xD;
          -  Concurrent oral multivitamins allowed (i.e., Centrum or One a Day)&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of allergy to calcitriol, paricalcitol, or other Vitamin D compounds&#xD;
&#xD;
          -  History of drug or alcohol abuse within the past 6 months&#xD;
&#xD;
          -  History of other malignancy except inactive nonmelanoma skin cancer, adequately&#xD;
             treated stage I or II cancer from which the patient is currently in complete&#xD;
             remission, or other cancer if the patient has been disease-free for 5 or more years&#xD;
&#xD;
          -  Serious medical illness that would limit survival to &lt; 3 months&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral or fungal infection&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  Concurrent supplemental calcium&#xD;
&#xD;
          -  Concurrent digitalis compounds&#xD;
&#xD;
          -  Concurrent chemotherapy&#xD;
&#xD;
          -  Concurrent biologic therapy, including trastuzumab and bevacizumab&#xD;
&#xD;
          -  Concurrent hormonal agents for breast cancer except luteinizing hormone-releasing&#xD;
             hormone agonists&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia A. Lawrence</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan A. Melin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>March 17, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

